BIOCRYST PHARMACEUTICALS INC (BCRX) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026before open 35 8-K
Q2 FY2026Wed, Aug 5, 2026before open 36 8-K
Q1 FY2026Wed, May 6, 2026before open 36 8-K
Q4 FY2025Thu, Feb 26, 2026before open 57 8-K
Q3 FY2025Mon, Nov 3, 2025before open 34 8-K
Q2 FY2025Mon, Aug 4, 2025before open 35 8-K
Q1 FY2025Mon, May 5, 2025before open 35 8-K
Q4 FY2024Mon, Feb 24, 2025before open 55 8-K

What they guided beta

Q3 FY2026 "EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 BioCryst Reports Third Quarter 2026 Financial Results — Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — — Improved Non-GAAP operating expense guidance to $415 to $425 million — — Received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older" exhibit
Q3 FY2026 "The program remains on track to report top-line results at six- and twelve-month endpoints in Q3 2027." exhibit
Q3 FY2026 "The company has enrolled Part 4 of this trial and expects to report initial data in patients with NS by the end of 2026." exhibit
Q3 FY2026 "Financial Outlook for 2026 The company maintained its outlook for full year 2026 global net ORLADEYO revenue of $625 million to $645 million and increased its full year 2026 total revenue outlook, including revenue from RAPIVAB ® (peramivir injection) and the licensing of navenibart European rights, to $715 million to $730 million." exhibit
Q3 FY2026 "The company improved its outlook for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to $415 million to $425 million." exhibit
Q2 FY2026 "EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 BioCryst Reports Second Quarter 2026 Financial Results — Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — — Began shipping ORLADEYO oral pellets to pediatric patients on August 3 — — Completed enrollment in ALPHA-ORBIT, the ongoing pivotal study of navenibart — R" exhibit
Q2 FY2026 "The program remains on track to report top-line results from both doses in Q3 2027." exhibit
Q2 FY2026 "The company is dosing in Part 4 of this trial, which will enroll up to 12 patients for three months, and expects to report data from this part by the end of 2026." exhibit
Q2 FY2026 "Financial Outlook for 2026 The company maintained its outlook for full year 2026 global net ORLADEYO revenue of $625 million to $645 million." exhibit
Q2 FY2026 "The company raised the full year 2026 total revenue outlook, including RAPIVAB ® (peramivir injection) and revenue from the licensing of navenibart European rights, to $690 million to $715 million." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/BCRX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/BCRX

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

BCRX earnings date badge

HTML

<a href="https://veritasdata.dev/company/BCRX/"><img src="https://veritasdata.dev/embed/BCRX.svg" alt="BCRX earnings date" width="240" height="56"></a>

Markdown

[![BCRX earnings date](https://veritasdata.dev/embed/BCRX.svg)](https://veritasdata.dev/company/BCRX/)

Script

<script async src="https://veritasdata.dev/embed/BCRX.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/BCRX"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.